Notably, durvalumab, an anti-PD-L1 inhibitor, demonstrated significant improvements in both overall survival (OS) and progression-free survival (PFS) following CRT in the PACIFIC and ADRIATIC trials (106, 107), which established its therapeutic potential in lung cancer. Here, CD274 is linked to lung carcinoma.